Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

1287

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation (AF)
Stroke

Interventions

BIOLOGICAL: Abelacimab
DRUG: Rivaroxaban

Sponsor

Anthos Therapeutics, Inc.

Collaborators

[object Object]